What question did this study set out to answer?

The review aims to summarize the therapeutic effects of parthenolide and its derivatives on respiratory tract diseases, focusing on molecular mechanisms.

April 11, 2026Open Access

Parthenolide and Its Derivatives in the Treatment of Respiratory Tract Diseases: Therapeutic Effects and Molecular Mechanisms

YYYizhu YaoWenzhou Medical University YYi-jiaCentral South University PCPing ChenWenzhou Medical University

Key Points

The review aims to summarize the therapeutic effects of parthenolide and its derivatives on respiratory tract diseases, focusing on molecular mechanisms.
Literature review of studies from PubMed, Web of Science, and Scopus up to February 2026.
Analysis of pharmacological mechanisms involving key signaling pathways such as STAT3 and NF-κB.
Examination of clinical application advancements and drug delivery methods for parthenolide derivatives.
Parthenolide and derivatives show significant therapeutic effects in lung cancer, pulmonary fibrosis, asthma, pneumonia, and acute lung injury.
Clinical translation progress of ACT001 was highlighted, showcasing its safety and pharmacokinetic profiles.
Discussion of emerging drug delivery systems like micelles and their potential to enhance treatment efficacy.

Abstract

Yizhu Yao, Yijia Wang, Ping Chen, Dan Yao, Xiaoying Huang, Liangxing Wang Division of Pulmonary Medicine, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, Peopleâs Republic of ChinaThese authors contributed equally to this workCorrespondence: Liangxing Wang, Division of Pulmonary Medicine, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, Peopleâs Republic of China, Email wangliangxing@wzhospital.cn Xiaoying Huang, Division of Pulmonary Medicine, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, Peopleâs Republic of China, Email huangxiaoying@wzhospital.cnAbstract: Parthenolide (PTN), a sesquiterpene lactone derived from the medicinal plant feverfew (Tanacetum parthenium), and its derivatives such as dimethylamino parthenolide (DMAPT) and dimethylaminomicheliolide fumarate (ACT001) exhibit distinguished anti-inflammatory, anticancer, antioxidant, and epigenetic activities, with accumulating evidence demonstrating their therapeutic potential in respiratory diseases. This review systematically summarizes the antitumor, anti-inflammatory, antioxidative, and antifibrotic effects of PTN and its derivatives in relevant animal models, elucidates the underlying pharmacological mechanisms involving STAT3, NF-ÎºB, MAPK/ERK, and PI3K signaling pathways, and highlights recent advances in clinical applications and drug delivery strategies. A comprehensive literature search was conducted in PubMed, Web of Science, and Scopus up to February 2026. Results demonstrate that PTN and its derivatives exert significant therapeutic effects in lung cancer, pulmonary fibrosis, asthma, pneumonia, and acute lung injury. We summarize the clinical translation progress of ACT001, including its safety and pharmacokinetic profiles, discuss emerging delivery systems such as micelles, and review the patent landscape of PTN derivatives. By integrating mechanistic insights with progress in clinical applications and drug delivery, this review provides a foundation for further mechanistic studies and supports the translational development of PTN-based therapies for respiratory disorders. Keywords: parthenolide, DMAPT, ACT001, anti-inflammatory agents, respiratory tract diseases

KI fragen

Bookmark

View Full Paper